Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
45
BNR Quote, Financials, Valuation and Earnings
Last price:
$21.52
Seasonality move
:
5.23%
Day range:
$19.75 - $21.57
52-week range:
$2.18 - $24.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.02x
P/B ratio:
3.52x
Volume:
18.1K
Avg. volume:
68.3K
1-year change:
200.72%
Market cap:
$228M
Revenue:
$71.7M
EPS (TTM):
-$1.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BNR
Burning Rock Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$130.3M | -$0.23 | 16.18% | -46.43% | $49.17 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BNR
Burning Rock Biotech Ltd.
|
$21.18 | -- | $228M | -- | $0.00 | 0% | 3.02x |
|
ADAG
Adagene, Inc.
|
$1.78 | $9.22 | $83.9M | -- | $0.00 | 0% | 801.10x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.79 | $4.00 | $16.2M | -- | $0.00 | 0% | 0.46x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.29 | -- | $4.2M | -- | $0.00 | 0% | 1.04x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$18.33 | $49.17 | $2B | -- | $0.00 | 0% | 4.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BNR
Burning Rock Biotech Ltd.
|
5.69% | 3.312 | 5% | 2.82x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BNR
Burning Rock Biotech Ltd.
|
$13.8M | -$2.3M | -18.96% | -20.71% | -12.26% | $2.2M |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Burning Rock Biotech Ltd. vs. Competitors
-
Which has Higher Returns BNR or ADAG?
Adagene, Inc. has a net margin of -12.73% compared to Burning Rock Biotech Ltd.'s net margin of --. Burning Rock Biotech Ltd.'s return on equity of -20.71% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital BNRBurning Rock Biotech Ltd.75.1% -$0.22 $81.9M ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About BNR or ADAG?
Burning Rock Biotech Ltd. has a consensus price target of --, signalling upside risk potential of 84.74%. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 418.22%. Given that Adagene, Inc. has higher upside potential than Burning Rock Biotech Ltd., analysts believe Adagene, Inc. is more attractive than Burning Rock Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BNRBurning Rock Biotech Ltd.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is BNR or ADAG More Risky?
Burning Rock Biotech Ltd. has a beta of 1.199, which suggesting that the stock is 19.932% more volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BNR or ADAG?
Burning Rock Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Burning Rock Biotech Ltd. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNR or ADAG?
Burning Rock Biotech Ltd. quarterly revenues are $18.4M, which are larger than Adagene, Inc. quarterly revenues of --. Burning Rock Biotech Ltd.'s net income of -$2.3M is higher than Adagene, Inc.'s net income of --. Notably, Burning Rock Biotech Ltd.'s price-to-earnings ratio is -- while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Burning Rock Biotech Ltd. is 3.02x versus 801.10x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNRBurning Rock Biotech Ltd.3.02x -- $18.4M -$2.3M ADAGAdagene, Inc.801.10x -- -- --
-
Which has Higher Returns BNR or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -12.73% compared to Burning Rock Biotech Ltd.'s net margin of -353.92%. Burning Rock Biotech Ltd.'s return on equity of -20.71% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital BNRBurning Rock Biotech Ltd.75.1% -$0.22 $81.9M CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About BNR or CASI?
Burning Rock Biotech Ltd. has a consensus price target of --, signalling upside risk potential of 84.74%. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 406.65%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Burning Rock Biotech Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Burning Rock Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BNRBurning Rock Biotech Ltd.0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is BNR or CASI More Risky?
Burning Rock Biotech Ltd. has a beta of 1.199, which suggesting that the stock is 19.932% more volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock BNR or CASI?
Burning Rock Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Burning Rock Biotech Ltd. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNR or CASI?
Burning Rock Biotech Ltd. quarterly revenues are $18.4M, which are larger than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Burning Rock Biotech Ltd.'s net income of -$2.3M is higher than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Burning Rock Biotech Ltd.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Burning Rock Biotech Ltd. is 3.02x versus 0.46x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNRBurning Rock Biotech Ltd.3.02x -- $18.4M -$2.3M CASICASI Pharmaceuticals, Inc.0.46x -- $3.1M -$10.9M
-
Which has Higher Returns BNR or CPHI?
China Pharma Holdings, Inc. has a net margin of -12.73% compared to Burning Rock Biotech Ltd.'s net margin of -86.16%. Burning Rock Biotech Ltd.'s return on equity of -20.71% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital BNRBurning Rock Biotech Ltd.75.1% -$0.22 $81.9M CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About BNR or CPHI?
Burning Rock Biotech Ltd. has a consensus price target of --, signalling upside risk potential of 84.74%. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Burning Rock Biotech Ltd. has higher upside potential than China Pharma Holdings, Inc., analysts believe Burning Rock Biotech Ltd. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BNRBurning Rock Biotech Ltd.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is BNR or CPHI More Risky?
Burning Rock Biotech Ltd. has a beta of 1.199, which suggesting that the stock is 19.932% more volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock BNR or CPHI?
Burning Rock Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Burning Rock Biotech Ltd. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNR or CPHI?
Burning Rock Biotech Ltd. quarterly revenues are $18.4M, which are larger than China Pharma Holdings, Inc. quarterly revenues of $756.2K. Burning Rock Biotech Ltd.'s net income of -$2.3M is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, Burning Rock Biotech Ltd.'s price-to-earnings ratio is -- while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Burning Rock Biotech Ltd. is 3.02x versus 1.04x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNRBurning Rock Biotech Ltd.3.02x -- $18.4M -$2.3M CPHIChina Pharma Holdings, Inc.1.04x -- $756.2K -$651.5K
-
Which has Higher Returns BNR or SVA?
Sinovac Biotech Ltd. has a net margin of -12.73% compared to Burning Rock Biotech Ltd.'s net margin of --. Burning Rock Biotech Ltd.'s return on equity of -20.71% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital BNRBurning Rock Biotech Ltd.75.1% -$0.22 $81.9M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About BNR or SVA?
Burning Rock Biotech Ltd. has a consensus price target of --, signalling upside risk potential of 84.74%. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Burning Rock Biotech Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe Burning Rock Biotech Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BNRBurning Rock Biotech Ltd.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is BNR or SVA More Risky?
Burning Rock Biotech Ltd. has a beta of 1.199, which suggesting that the stock is 19.932% more volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock BNR or SVA?
Burning Rock Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Burning Rock Biotech Ltd. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios BNR or SVA?
Burning Rock Biotech Ltd. quarterly revenues are $18.4M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. Burning Rock Biotech Ltd.'s net income of -$2.3M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, Burning Rock Biotech Ltd.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Burning Rock Biotech Ltd. is 3.02x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNRBurning Rock Biotech Ltd.3.02x -- $18.4M -$2.3M SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns BNR or ZLAB?
Zai Lab Ltd. has a net margin of -12.73% compared to Burning Rock Biotech Ltd.'s net margin of -30.98%. Burning Rock Biotech Ltd.'s return on equity of -20.71% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital BNRBurning Rock Biotech Ltd.75.1% -$0.22 $81.9M ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About BNR or ZLAB?
Burning Rock Biotech Ltd. has a consensus price target of --, signalling upside risk potential of 84.74%. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.17 which suggests that it could grow by 168.25%. Given that Zai Lab Ltd. has higher upside potential than Burning Rock Biotech Ltd., analysts believe Zai Lab Ltd. is more attractive than Burning Rock Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings BNRBurning Rock Biotech Ltd.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is BNR or ZLAB More Risky?
Burning Rock Biotech Ltd. has a beta of 1.199, which suggesting that the stock is 19.932% more volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock BNR or ZLAB?
Burning Rock Biotech Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Burning Rock Biotech Ltd. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNR or ZLAB?
Burning Rock Biotech Ltd. quarterly revenues are $18.4M, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Burning Rock Biotech Ltd.'s net income of -$2.3M is higher than Zai Lab Ltd.'s net income of -$36M. Notably, Burning Rock Biotech Ltd.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Burning Rock Biotech Ltd. is 3.02x versus 4.45x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNRBurning Rock Biotech Ltd.3.02x -- $18.4M -$2.3M ZLABZai Lab Ltd.4.45x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
